Search Results
Sep 17, 2025, 08:00 ET Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
skin clearance vs placebo (Week 16) and deucravacitinib (Weeks 16 and 24).1Icotrokinra demonstrated similar adverse event rates (AEs) to placebo, with no new safety signals identified. Icotrokinra AE rates were numerically lower vs deucravacitinib through Week 24.1"These
More news about: Johnson & Johnson
Sep 17, 2025, 07:00 ET BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
OLE, regardless of dosing regimen (BKZ Total). ≠mNRI: Patients discontinuing due to lack of efficacy, treatment-related AEs were considered non-responder; multiple imputation was used for other missing data. Proportion of patients reported from the BE RADIANT Phase 3b
More news about: UCB
Sep 16, 2025, 19:30 ET Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
higher oral drug exposures. - ASC30 is safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs). There was no vomiting incidence in multiple ascending dose (MAD) cohort 1 due to 2 mg to 5 mg weekly titration strategy.
More news about: Ascletis Pharma Inc.
Sep 16, 2025, 09:59 ET memoryBlue proves lasting customer impact with 23% longer retention, 38% lifetime revenue growth and expanding global services
community of 1,200+ alumni who remain connected long after their time at the company, memoryBlue can source proven sales talent at every level—SDRs, ISRs, AEs and sales leaders.Through the Hire Out program, customers can convert standout reps into full-time roles, preserving momentum and reducing
More news about: memoryBlue
Sep 11, 2025, 09:15 ET PAN GLOBAL TRIFFT BEIM CÁRMENES-PROJEKT IN SPANIEN AUF 3,01 G/T GOLD AUF 34 METERN DICHT UNTER DER OBERFLÄCHE, DARUNTER AUCH 8,93 G/T GOLD ÜBER 5 METER
Au-ICP-24), und die Multielementanalyse wurde mittels 4-Säure-Aufschluss mit ICP-AES-Abschluss (Methode ME-ICP-61) durchgeführt. Die Ergebnisse der oberflächennahen Basismetalle wurden mit einem 4-Säuren-Aufschluss mit ICP-AES (Methode OG-62) untersucht.
More news about: Pan Global Resources Inc.
Sep 10, 2025, 16:15 ET Endo Presents Plantar Fibromatosis and Plantar Fasciitis Data at the American Orthopaedic Foot & Ankle Society Annual Meeting
PFA. The safety profile aligned with known adverse events (AE) and were mostly rated mild to moderate. Higher CCH doses had more frequent and severe AEs. CCH treatment showed improvements across all effectiveness measures compared to placebo, though significance was not assessed. These results supported
More news about: Endo USA, Inc.